Clinical trials
NPC clinical trials
Below are recruiting npc clinical trials, each written for real people, not researchers. We’re tracking 78 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07277764RecruitingPhase 2
Radiation and immunotherapy for returning nasopharyngeal cancer
This trial tests a combination of high and low dose radiation plus an immunotherapy drug (PD-1 inhibitor) for people whose nasopharyngeal cancer has come back after previous treatment. The goal is to see if this approach can be more effective while reducing side effects.
Nanchang, JiangxiAges 18–75 - NCT07236190RecruitingPhase 2
Testing NPC-1 for people with Alzheimer's signs
This study tests whether a medicine called NPC-1 can help people with mild memory or thinking problems or early-stage Alzheimer's. It looks at a blood marker to see if the treatment may slow down the disease.
Boston, MassachusettsAges 55 years+ - NCT07235319RecruitingPhase 3
Immediate vs delayed radiation after chemo-immunotherapy for metastatic NPC
This trial tests whether giving radiation therapy to the main tumor right after chemo-immunotherapy is better than waiting until the cancer comes back, in people with newly diagnosed metastatic nasopharyngeal cancer. It aims to see which approach helps you live longer and have fewer side effects.
Guangzhou, GuangdongAges 18–70 - NCT06752239RecruitingPhase 3
Optimizing radiation to protect thyroid in nasopharyngeal cancer
This trial tests a way to adjust radiation therapy to better protect the thyroid gland during treatment for nasopharyngeal carcinoma. It aims to reduce thyroid damage while still effectively treating the cancer.
Nanchang, JiangxiAges 18–70 - NCT06912698RecruitingPhase 3
Lower vs. standard radiation for early nasopharyngeal cancer
This trial compares a lower dose of radiation to the standard dose for people with early-stage nasopharyngeal cancer. It aims to see if a lower dose is just as effective while reducing side effects.
Guangzhou, GuangdongAges 18–70 - NCT07188584RecruitingPhase 3
Smaller radiation vs. standard after chemo-immunotherapy for advanced nasopharyngeal cancer
This trial tests whether a smaller radiation treatment area is as effective as the usual larger one for people whose metastatic nasopharyngeal cancer has responded well to first-line chemotherapy plus immunotherapy. It aims to reduce side effects while keeping the cancer under control.
ZhuhaiAges 18–70 - NCT06909799Recruiting
NAC to prevent lung damage after TB treatment
This trial tests if taking N-acetylcysteine (NAC) alongside standard TB treatment can help prevent long-term lung problems after tuberculosis. It is for people with moderate to severe TB who already have some reduced lung function.
Fajara, The GambiaAges 18–65 - NCT07154069RecruitingPhase 3
Immunotherapy for advanced nasopharyngeal cancer after chemo
This trial tests if adding an immunotherapy drug (PD-1 inhibitor) after standard induction chemotherapy helps keep advanced nasopharyngeal cancer from coming back. It is for people who have completed 3 cycles of GP chemotherapy combined with a PD-1 inhibitor and have not had their cancer progress.
Guangzhou, GuangdongAges 18–65 - NCT07137052Recruiting
Precise adaptive radiotherapy for nasopharyngeal cancer
This trial tests a more precise form of radiation therapy (adaptive radiotherapy) for nasopharyngeal cancer. It is designed for patients who have not yet had any treatment and whose cancer is limited to the head and neck area.
XiamenAges 18–70 - NCT07085988RecruitingPhase 2
Nutrition help for nasopharyngeal cancer patients on chemoradiation
This trial tests if special nutritional management during concurrent chemoradiotherapy can improve outcomes for people with nasopharyngeal cancer. If you are getting both chemotherapy and radiation as your main treatment, this study may help you maintain better nutrition.
Nanchang, JiangxiAges 18 years+ - NCT07082725RecruitingPhase 3
Study of oral nizubaglustat for Niemann-Pick type C
This study tests an oral medication called nizubaglustat for people with Niemann-Pick type C disease who cannot take or are not satisfied with the current treatment miglustat. It aims to see if the drug can help with symptoms like coordination and movement problems.
Oakland, CaliforniaAges 4 years+ - NCT04812431RecruitingPhase 1/Phase 2
Tested stem cell transplant therapy for severe spinal cord injury
This trial tests a cell transplant approach for people with a very severe spinal cord injury. It focuses first on safety and also looks for early signs the therapy may improve function.
Suwon, GyeonggidoAges 18–65 - NCT07072143Recruiting
Study on children with rare tumors
This study is looking at children and teens with very rare tumors to learn more about these conditions and improve future care. It aims to gather information from patients treated at participating centers.
Padova, ItalyAges birth–18 years - NCT07067268RecruitingPhase 2
Tislelizumab and capecitabine for nasopharyngeal cancer with remaining EBV DNA
This trial tests a combination of two drugs, tislelizumab and capecitabine, for people with nasopharyngeal cancer who still have detectable EBV DNA in their blood after finishing radiation therapy. The goal is to see if this treatment can help clear the virus and improve outcomes.
Shanghai, ChinaAges 18 years+ - NCT06749899RecruitingPhase 3
Immunotherapy with chemoradiation for advanced nasopharyngeal cancer
This trial tests a combination of a new immunotherapy (QL1706) plus standard chemoradiation for people with advanced nasopharyngeal cancer that hasn't spread to distant organs. The goal is to see if adding this drug helps control the cancer better than standard treatment alone.
Fuzhou, FujianAges 18–65 - NCT07013461Recruiting
Nasopharyngeal cancer staging study
This study looks at how well the current cancer staging system works for nasopharyngeal cancer. If you have been diagnosed with this type of cancer between October 2025 and September 2026, you may be able to join.
Shenzhen, GuangdongAges 18 years+ - NCT06235203RecruitingPhase 3
Comparing treatment timing in recurrent nasopharyngeal cancer
This trial compares giving chemotherapy and immunotherapy before surgery (neoadjuvant) versus after surgery (adjuvant) for patients whose nasopharyngeal cancer has returned locally. It aims to find which approach works better to control the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06676722RecruitingPhase 2
SBRT and two targeted drugs for advanced nasopharyngeal cancer
This trial tests a combination of focused radiation (SBRT) and two targeted drugs (nimotuzumab and tislelizumab) for people with nasopharyngeal cancer that has come back or spread to a few spots (1-5) after prior immunotherapy. It aims to see if this triple therapy can help control the disease when standard treatment has stopped working.
Xiamen, FujianAges 18–75 - NCT06228079RecruitingPhase 3
Chemo-immunotherapy after surgery for early reoccurring nasopharyngeal cancer
This study looks at whether adding chemo-immunotherapy after surgery is better than surgery alone for patients whose nasopharyngeal cancer has returned but is still in early stages. It may help prevent the cancer from coming back again.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06839066RecruitingPhase 2
HLX43 for advanced nasopharyngeal cancer after prior treatments
This trial tests an investigational drug called HLX43 for people with nasopharyngeal cancer that has come back or spread, and who have already tried two or more prior treatments without success. The goal is to see if HLX43 can shrink tumors or slow the cancer's growth.
Fuzhou, FujianAges 18 years+ - NCT06802835RecruitingPhase 1/Phase 2
EGFR antibody plus immunotherapy and chemo for advanced nasopharyngeal cancer
This trial tests a combination of an EGFR antibody, a PD-1 inhibitor, and chemotherapy for people with nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this new mix can help shrink tumors or slow the disease.
Guangzhou, GuangdongAges 18–75 - NCT06763640Enrolling by invitation
TILs as a predictor in nasopharyngeal cancer
This study looks at how immune cells called TILs (tumor-infiltrating lymphocytes) in your tumor tissue might predict outcomes for nasopharyngeal cancer. It may help doctors better understand your cancer and guide future treatment decisions.
Nanchang, JiangxiAges 18–70 - NCT06177301RecruitingPhase 3
Comparing two drug combos for recurrent nasopharyngeal cancer
This study compares two combinations of drugs (tislelizumab plus either GX or GP) to see which works better for people with nasopharyngeal cancer that has returned or spread and has not been treated with systemic therapy before.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06592599RecruitingPhase 2
Drug combo for EBV-related nasopharyngeal cancer
This trial tests a combination of three drugs (gemcitabine, docetaxel, and toripalimab) as a first treatment for a type of nasopharyngeal cancer linked to the Epstein-Barr virus. The goal is to see if this combination helps shrink tumors before other treatments like radiation.
Palo Alto, CaliforniaAges 18 years+
Hear when a new NPC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for npc?
- Yes. Clin2 currently lists 78 recruiting npc studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a npc trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a npc trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.